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IL-22The prevalence of life-threatening anaphylactic responses to food is rising at an alarming rate. The
emerging role of the gut microbiota in regulating food allergen sensitization may help explain this
trend. The mechanisms by which commensal bacteria inﬂuence sensitization to dietary antigens are
only beginning to be explored. We have found that a population of mucosa-associated commensal
anaerobes prevents food allergen sensitization by promoting an IL-22-dependent barrier protective
immune response that limits the access of food allergens to the systemic circulation. This early
response is followed by an adaptive immune response mediated in part by an expansion of Foxp3+
Tregs that fortiﬁes the tolerogenic milieu needed to maintain non-responsiveness to food. Bacterial
metabolites, such as short-chain fatty acids, may contribute to the process through their ability to
promote Foxp3+ Treg differentiation. This work suggests that environmentally induced alterations
of the gut microbiota offset the regulatory signals conferred by protective bacterial species to
promote aberrant responses to food. Our research presents exciting new possibilities for preventing
and treating food allergies based on interventions that modulate the composition of the gut
microbiota.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Differentiating innocuous environmental antigens from serious
threats is a particular challenge in the intestinal mucosa, which is
constantly exposed to antigens derived from both food and the
commensal microbiota. Oral tolerance typically refers to the
process by which the immune system limits the response to
dietary antigens. Experimentally, administration of antigen by
the oral route induces mucosal and systemic non-responsiveness
to subsequent peripheral challenge [1]. Rodent models have pro-
vided insight into the physiological processes required to maintain
tolerance to food and suggest that sensitization to dietary allergens
increases when these processes fail.
Since nutrients are absorbed in the small intestine studies on
the mechanisms regulating oral tolerance have focused primarily
on antigen-speciﬁc immune responses in the gut associated
lymphoid tissues (GALT) that drain this site. Emerging evidence,
however, points to a central role for commensal bacteria in pre-
venting food allergen sensitization. Dietary antigens share the
intestinal lumen with trillions of astoundingly diverse bacteriacomprising approximately one thousand different species [2].
These bacteria colonize the gut at increasing densities from
stomach to rectum. In the small intestine, bacterial load is kept
low due to the high motility of intestinal contents and the bacteri-
cidal activity of bile salts, with densities of 104–105 bacteria per
milliliter of efﬂuent in the proximal small intestine and 108 bacte-
ria per milliliter of efﬂuent in the ileum [3]. Bacterial load is by far
greatest in the colon, where densities can reach 1011 organisms per
gram of luminal content [3]. The high microbial content of the
ileum and colon exerts a formidable inﬂuence on the framework
of the mucosal immune system in the gut, not only to promote
local homeostatic interactions, but also to modulate immune
responses to antigens at peripheral sites beyond the mucosa. We
have found that particular populations of bacteria are required to
prevent sensitization to dietary antigens; when protective
bacteria-derived signals are lacking, tolerance to dietary antigen
is not induced. Our data support the idea that an environmentally
induced alteration of the commensal microbiota is driving the rap-
idly increasing prevalence of allergic responses to food in Western
societies [4].
In this review, we will ﬁrst discuss what is currently known
about the regulation of tolerance to dietary antigen before discuss-
ing how commensal bacteria inﬂuence this process.
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The mechanisms governing non-responsiveness to dietary
antigens remain poorly understood; the ways in which dietary
antigens cross the intestinal epithelial barrier, are presented to
the immune system, and elicit a response are still being deﬁned.
It is clear, however, that the maintenance of tolerance involves
both cellular and humoral processes that are induced in the intes-
tinal lamina propria (LP) and the mesenteric lymph node (MLN). In
order to be recognized by the immune system dietary antigenmust
ﬁrst cross the epithelium of the small intestine. Antigen can be
transcytosed by specialized epithelial cells called microfold (M)
cells, which reside in the follicle-associated epithelium of Peyer’s
patches (PP) [5]. M cells lack the brush border glycocalyx present
on other enterocytes and instead contain large vesicles in their
cytoplasm that enable transepithelial transport of luminal antigens
[6,7]. The basolateral surface of M cells is in close contact with the
underlying GALT where antigen presenting cells (APCs) can take up
and process these luminal antigens for presentation to naïve T cells
[8].
M cells were initially thought to be the major route by which
dietary antigens cross the epithelial barrier. More recent evidence,
however, suggests that other types of epithelial cells may assist in
this process. Goblet cells, best known for their ability to produce
the thick mucus glycocalyx overlaying the epithelium, may play
a role in antigen transport. Fluorescent imaging techniques indi-
cate that goblet cell-associated passages (GAPs) allow labeled,
orally delivered antigen to cross from the lumen into the LP [9].
This process is constitutively active in the small intestine, suggest-
ing that GAPs may be an important, underappreciated route for
antigen uptake. In addition to active transport through enterocytes,
antigen can pass between epithelial cells. Intestinal epithelial cells
(IECs) are joined by tight junctions, adherens junctions, and
desmosomes that together form a ‘‘molecular gasket’’ to seal the
paracellular space [10]. Under homeostatic conditions, solutes,
proteins, and certain microbial components can inﬁltrate this com-
plex and pass between cells. Paracellular transport is regulated clo-
sely by the cytokine milieu, which can dramatically alter the
expression of tight junction proteins under conditions of inﬂam-
mation [10]. Some evidence also suggests that extensions from a
subset of dendritic cells (DC) in the small intestine reach through
epithelial tight junctions to sample luminal antigens [11–13].
Once antigen has passed from the intestinal lumen into the
GALT it is taken up by APCs for presentation to naïve T cells. Sev-
eral functionally distinct subsets of APCs in the GALT can be
deﬁned by their surface marker expression. Two major populations
have been implicated in oral tolerance: a DC subset identiﬁed by
the expression of CD11c and CD103 and a macrophage subset
deﬁned by the expression of CD11b and CX3CR1 [1]. CD11c+
CD103+ DCs express high levels of MHC class II and the homing
receptor CCR7 that enables migration to the MLN [14,15]. CD11c+
CD103+ CCR7+ DCs are the major cell population responsible for
picking up and processing antigens crossing the epithelial barrier
[16,17]. Once antigen has been processed, these DCs trafﬁc through
the lymph to the MLN where they encounter and stimulate naïve
CD4+ T cells. The fate of an antigen-speciﬁc CD4+ T cell following
stimulation depends upon the cytokine milieu in which the
encounter occurs. Under homeostatic conditions, high concentra-
tions of TGF-b and retinoic acid (RA) in the MLN promote a tolero-
genic environment that favors the differentiation of regulatory T
cells (Tregs) [18,19]. The TGF-b required for this process is pro-
duced both by CD103+ DCs themselves as well as by IECs [20,21].
Interestingly, IEC-derived TGF-b has been shown to be important
for promoting TGF-b production by CD103+ DCs and enhancing
their ability to drive Treg differentiation [22]. RA is derived fromdietary vitamin A and is metabolized primarily by CD11c+CD103+
DCs, which express high levels of retinaldehyde dehydrogenase
(RALDH) and aldehyde dehydrogenase (ALDH) enzymes [18,19].
RA enhances the TGF-b dependent upregulation of Foxp3, the tran-
scription factor that controls Treg differentiation [18]. In the
absence of dietary vitamin A, the frequency of Tregs in the MLN
and intestinal LP is signiﬁcantly reduced [23,24].
Of the two major APC subsets in the GALT, the role of CX3CR1+
macrophages has been controversial. Using an in vitro transwell
system, Rescigno et al ﬁrst visualized the ability of a subset of
DCs to extend their dendrites between epithelial tight junctions
[12]. This ﬁnding was corroborated using confocal microscopy,
which found the dendrites to extend primarily in the villi of the
terminal ileum. The DC subset involved was later characterized
as CD11c+ CD11b+ CX3CR1+ DCs that derived from myeloid precur-
sors [11]. However, some question remained as to the role of these
cells in oral tolerance, as they were shown to be poor APCs for the
stimulation of T cell proliferation in vitro [25]. Moreover, CX3CR1+
DCs do not migrate under homeostatic conditions and have been
observed in the MLN only after infection with an intestinal patho-
gen or following antibiotic treatment [26]. Given these characteris-
tics, CX3CR1+ cells are thought to be more representative of a
macrophage rather than a DC subset. Yet, their importance in
establishing oral tolerance is clear; in the absence of CX3CR1
expression, the uptake of fed antigen and the expansion of cognate
T cells is reduced, resulting in increased delayed-type hypersensi-
tivity (DTH) reactions in response to antigen challenge [27]. Recent
work suggests that CX3CR1+ macrophages are the ﬁrst to acquire
luminal antigen, which they then pass via cell-to-cell contact and
gap junctions to CD103+ DCs that migrate and interact with naïve
T cells [27]. Other work suggests that the major function of these
cells is to produce IL-10, which supports the proliferation and
expansion of antigen-speciﬁc Foxp3+ Tregs in the LP [28].
After dietary antigen-speciﬁc T cells recognize their cognate
antigen and differentiate into Foxp3+ Tregs, they upregulate the
homing molecules CCR9 and a4b7 that direct migration back to
the small intestinal LP [28,29]. Once there, Foxp3+ Tregs expand
and suppress aberrant responses to dietary antigens through the
production of IL-10, TGF-b, and IL-35 [30]. In the absence of
induced Tregs, the cytokine milieu of the MLN is highly Th2-
skewed with increases in CD4+ T cells producing IL-4, IL-13 and
IL-5 [31]. Food allergen sensitization occurs when naïve CD4+ T
cells differentiate into Th2 cells in the presence of IL-4 [32]. Th2
cells then help to promote an allergic response by inducing B cell
class-switching to the IgE isotype. IgE subsequently binds to its
high afﬁnity Fc receptor, FceRI, which is expressed predominantly
on mast cells. Re-exposure to dietary antigen crosslinks bound IgE,
inducing mast cell degranulation and the release of mediators that
precipitate an allergic, and potentially anaphylactic, reaction [33].
The cytokine environment may not be the only factor regulating
tolerance to food. Recent work suggests that mucus is more than
just a physical barrier between IECs and the intestinal lumen and
actively promotes tolerance by repressing the expression of
inﬂammatory cytokines by DCs [34]. In the presence of the mucin
protein MUC2, DCs produce more IL-10 and express higher levels
of RALDH and ALDH enzymes. Mice deﬁcient in mucus production
(Muc2/mice) have a decreased proportion of Foxp3+ Tregs in the
LP and exhibit increased DTH responses after antigen feeding. This
effect of MUC2 is mediated by its binding to a galectin-3-dectin-1-
FccRIIB complex on DCs, activating b-catenin signaling to induce a
tolerogenic phenotype that contributes to mucosal homeostasis
[34].
Antibody secreting B cells also contribute to the induction of
oral tolerance. IgA is the most abundantly produced immunoglob-
ulin isotype and can be found in two forms: a monomeric form in
4260 S. Cao et al. / FEBS Letters 588 (2014) 4258–4266the systemic circulation and a dimeric form at mucosal sites [35].
IgA is uniquely suited for protection of mucosal sites like the GALT
because it is neutralizing but not inﬂammatory and binds luminal
antigens to prevent them from contacting the epithelial barrier or
the underlying immune system. In this way, IgA may reinforce oral
tolerance by excluding bound dietary components from the LP
[36]. Its necessity is debated, however, because there is no impair-
ment of tolerance when IgA is eliminated [36].
3. Commensal bacteria and sensitization to food allergens
What, then, is the role of the commensal bacteria in regulating
sensitization to dietary antigens? The mechanisms regulating
orally induced systemic non-responsiveness described above focus
solely on interactions between immune cells and dietary antigen in
the local environment of the small intestine and ignore the abun-
dance of bacteria colonizing the length of the intestinal tract. The
high microbial content of the intestine (and of the colon in partic-
ular) undoubtedly inﬂuences the underlying immune system in the
GALT. Indeed the GALT exhibits several specialized adaptations,
such as the secretion of antimicrobial proteins by IECs and the pro-
duction of secretory IgA, that act in concert to maintain tolerance
to the gut microbiota [37–39]. Whether commensal bacteria also
interact with the GALT to maintain non-responsiveness to the
other major luminal constituent – food – is only beginning to be
explored.
We have found that administration of broad-spectrum antibiot-
ics to neonatal mice induces sensitization to orally administered
peanut allergens, as characterized by increased levels of circulating
peanut-speciﬁc IgE and IgG1 [40,41]. 16S rRNA sequencing demon-
strates that antibiotic treatment markedly alters the composition
of the colonic and ileal microbiota, depleting most members of
the Bacteroidetes and Firmicutes phyla usually found to be preva-
lent in the gut. Notably, reconstituting the gut microbiota by trans-
fer of feces from an untreated mouse rescues antibiotic-treated
mice from food allergen sensitization. Moreover, colonizing antibi-
otic-treated mice with a microbiota enriched in Clostridia, an
indigenous class of anaerobic spore-forming Firmicutes that
resides in close proximity to the colonic epithelium, confers the
same protection [41]. These results indicate that certain signals
from the microbiota can prevent food allergen sensitization. This
concept is supported by work from other laboratories. Food
allergy-prone Il4raF709 mice with a gain-of-function mutation in
the IL-4 receptor attain a unique microbial signature upon OVA-
sensitization that is non-overlapping with that of sensitized wild-
type (WT) mice [42]. Transplantation of germ-free (GF) mice with
the microbiota of OVA-sensitized Il4raF709 mice, but not of OVA-
sensitized WTmice, results in a more severe anaphylactic response
upon challenge [42]. In another study, GF mice colonized with the
microbiota of a healthy human infant and sensitized with whey
protein exhibit milder allergic symptoms following challenge with
b-lactoglobulin than their GF counterparts [43].
As mentioned above, the prevalence of allergic responses to
food has been increasing in Western societies at an unprecedented
rate, rising by as much as 20% in a recent ten-year period [44–47].
The rapidity of this trend makes it unlikely that genetic drift alone
is responsible. Adherence to a Westernized lifestyle introduces
several environmental risk factors that can disturb the homeostatic
balance of the gut microbiota. These include excessive antibiotic
use, a shift towards formula-feeding and Caesarean births, and
consumption of a Western high fat diet. In particular, antibiotic
use during infancy has often been cited as a major factor contrib-
uting to the rising prevalence of allergic disease and is considered
among the most potent stimuli for perturbing bacterial communi-
ties throughout the gastrointestinal tract [48,49]. Indeed, increasedurinary levels of the antimicrobial agent triclosan are correlated
with a heightened risk of sensitization to food [50], and maternal
use of antibiotics before and during pregnancy is positively associ-
ated with an increased risk of cow’s milk allergy among newborns
[51]. Aside from antibiotic use, a greater risk of developing IgE-
mediated sensitization to food allergens has also been noted
among children delivered by Caesarean section [52]. Several stud-
ies have already reported signiﬁcant differences in the composition
of the microbiota of allergic versus non-allergic infants [53–56].
Collectively, these data provide clinical and epidemiological ﬁnd-
ings in support of a role for commensal dysbiosis in driving the
increasing prevalence of food allergy.
Few reports have built on this foundation, however, to examine
how microbiota-derived signals regulate sensitization to dietary
antigen. Our studies in gnotobiotic and antibiotic-treated murine
models have provided novel mechanistic insight into this question.
We have found that commensal bacteria prevent sensitization to
food allergens by inducing the differentiation of Foxp3+ Tregs
and the secretion of IgA and by regulating allergen uptake into
the systemic circulation through bacteria-induced IL-22 production.
4. Bacteria-induced Foxp3+ Tregs
In our mouse model, the protection against allergic sensitiza-
tion to food conferred by a Clostridia-containing microbiota is
associated with an increase in the proportion of Foxp3+ Tregs
among CD4+ T cells in the colonic LP and an increase in the concen-
tration of IgA in feces [41]. Both of these responses are indicative of
a protective adaptive immune response initiated by Clostridia col-
onization. In particular, the Clostridia-induced expansion of Foxp3+
Tregs may promote oral tolerance by quenching aberrant dietary
antigen-speciﬁc Th2 responses in the small intestine. Other work
has also reported that commensal bacteria direct naïve T cell dif-
ferentiation to the peripheral Foxp3+ Treg compartment. Colonic
Tregs possess a TCR repertoire distinct from that used by Tregs in
other locations, with some TCRs displaying reactivity to bacterial
antigens [57]. Furthermore, Clostridium clusters IV, XIVa and XVIII
[58,59] as well as Bacteroides fragilis [60] are potent inducers of
Foxp3+ Treg differentiation. The mechanisms by which bacteria
promote Foxp3+ Treg differentiation are starting to be elucidated.
Some evidence suggests that, as part of the indigenous mucosa-
associated microbiota, Clostridia induce a TGF-b rich environment
within the colon to enhance Foxp3+ Treg differentiation [59]. Bac-
teria-speciﬁc Foxp3+ Tregs may then direct anti-inﬂammatory
responses in the gut through the secretion of TGF-b, IL-10, and
IL-35, behaving similarly to their dietary antigen-speciﬁc counter-
parts [30].
5. Bacteria-induced IL-22 production
Our work suggests that Clostridia also play a novel role in pre-
venting food allergen sensitization by inducing the production of
the barrier protective cytokine IL-22. IL-22 is unusual in that it is
produced exclusively by hematopoietic cells while the expression
of its receptor is limited to non-hematopoietic cells and particu-
larly to epithelial cells of the mucosa [61,62]. IL-22 therefore medi-
ates a critical line of communication between the immune system
and the intestinal epithelium and is important for maintaining epi-
thelial barrier integrity during homeostasis and in response to
infection-mediated damage. Both CD4+ T cells and RORct+ innate
lymphoid cells (ILCs) produce IL-22. At steady state, mice lacking
RORct+ ILCs are more susceptible to microbial translocation from
the gut lumen to peripheral organs [63,64], an effect that can be
reversed by the administration of IL-22 [63]. During infection with
Citrobacter rodentium, mice lacking IL-22 exhibit defects in the
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burdens [65,66]. In both scenarios, the barrier protective effect of
IL-22 has been attributed to its ability to increase the production
of antimicrobial peptides including RegIIIb, RegIIIc, S100A8, and
S100A9 from IECs, thereby fortifying the intestinal barrier by
keeping pathogens and commensals at bay [63,65].
Although implicated in aberrant allergic responses to food, the
factors regulating epithelial barrier function remain unclear [67].
To gain insight into the mechanisms by which commensal bacteria
inﬂuence epithelial permeability to dietary antigens we isolated
IECs frommice colonized with Clostridia, which conferred maximal
protection against peanut allergen sensitization in our model, and
from mice colonized with a representative member of the Bacter-
oidetes, Bacteroides uniformis, which provided no protection
against sensitization [41]. Because our microarray analysis showed
that Clostridia colonization differentially upregulates the expres-
sion of RegIIIb and RegIIIc in isolated IECs, we examined whether
it also regulated IL-22 production in the colonic LP. We found that
Clostridia colonization induces the production of IL-22 by both
RORct+ ILCs and CD4+ T cells in the colonic LP. Since antigen uptake
from the intestinal lumen is the ﬁrst step in sensitization to a food
allergen, we reasoned that Clostridia-induced IL-22 production in
the intestinal LP reinforces the epithelial barrier to reduce perme-
ability to dietary proteins. Ara h 2 and Ara h 6, the immunodomi-
nant allergens of peanut (Arachis hypogaea), are resistant to
proteolytic degradation in vitro; their passage into the blood-
stream with secondary protein structure intact may potentiate
their allergenicity [68]. We therefore utilized sensitive capture ELI-
SAs to detect the transient presence of these allergens in the serum
within hours of oral gavage. We found that both Clostridia coloni-
zation and treatment with an IL-22 Fc fusion protein decreases
intestinal permeability to Ara h 2/6. Treatment of ClostridiaFig. 1. The process of maintaining non-responsiveness to food begins when dietary a
subsequently migrate to the mesenteric lymph node (MLN), where they encounter naïv
dietary antigen-speciﬁc Foxp3+ Tregs and upregulate expression of the gut-homing recept
Dietary antigen-speciﬁc Foxp3+ Tregs can then suppress aberrant responses to dietary ant
laboratory demonstrates that signals derived from Clostridia, a class of anaerobic spore-f
required to prevent sensitization to food allergens. Studies in gnotobiotic mice showed th
surge in IL-22 production from RORct+ innate lymphoid cells (ILCs). IL-22 acts on intesti
and reduce uptake of dietary antigen into the systemic circulation. This initial barrier pro
that includes IL-22+ CD4+ T cells, an expansion of Foxp3+ Tregs in the colonic lamina prcolonized mice with a neutralizing antibody to IL-22 demonstrated
that the effects of Clostridia on epithelial permeability to Ara h 2/6
are attributable to the actions of this cytokine. IL-22 from RORct+
ILCs is primarily responsible for this effect, since Rag1/mice col-
onized with Clostridia maintain barrier function while Rag1/
mice treated with an anti-CD90.2 monoclonal antibody to deplete
ILCs exhibit increased permeability to Ara h 2/6 [41]. In addition to
increasing the expression of antimicrobial peptides, IL-22 is known
to promote IEC proliferation [69,70] and mucus secretion by goblet
cells [71]. Given these general effects on barrier integrity, it is
likely that IL-22 blocks allergen uptake in an antigen non-speciﬁc
manner. Our data therefore suggest that Clostridia protect against
food allergen sensitization, in part, by regulating the access of die-
tary antigen to the systemic circulation. In our working model
(Fig. 1), colonization with Clostridia induces an early, innate, bar-
rier protective response mediated by IL-22 producing RORct+ ILCs,
followed by an adaptive immune response involving IL-22+CD4+ T
cells, Foxp3+CD4+ T cells and IgA secreting B cells that reinforces
the immunoregulatory environment needed to mediate tolerance
to dietary antigens.
6. A potential role for short-chain fatty acids
Microbial metabolites are increasingly appreciated as potent
regulators of immunity. Indeed, the gut is not only exposed to
the trillions of bacteria colonizing its surface but also to a myriad
of bacteria-derived compounds produced through the fermenta-
tion of dietary substrates [72]. In particular, short-chain fatty acids
(SCFAs) have received much attention for their immunoregulatory
capacity. SCFAs are a subset of fatty acids produced during the bac-
terial fermentation of indigestible dietary ﬁber. SCFA concentra-
tions are highest in the proximal colon, where they can be usedntigen crosses the intestinal epithelium. CD103+ DCs that have acquired antigen
e T cells. Within the tolerogenic environment of the MLN, T cells differentiate into
ors a4b7 and CCR9, which drive their migration back to the intestinal lamina propria.
igens through the production of the cytokines TGF-b, IL-10 and IL-35. Work from our
orming Firmicutes that resides in close proximity to the colonic epithelium are also
at Clostridia colonization induces an early barrier protective response mediated by a
nal epithelial cells to promote the production of antimicrobial peptides and mucus
tective response is then reinforced by a bacteria-induced adaptive immune response
opria and increased secretion of IgA into the intestinal lumen.
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the epithelium and into the bloodstream [73]. Acetate, propionate
and butyrate (acetic, propionic and butyric acids, respectively) are
the major SCFAs produced in the mammalian gut [73]. Recent work
has revealed an important role for SCFAs in promoting the differen-
tiation of colonic Foxp3+ Tregs. Administration of acetic, propionic
and butyric acids in the drinking water, either in combination or
individually, increases the frequency of Foxp3+ Tregs among
CD4+ T cells in the colonic LP, but not the spleen, MLN or thymus
of GF mice [74]. More recently, two groups have found butyrate
to be the most potent inducer of colonic Foxp3+ Tregs. Furusawa
et al. reported that a diet rich in butyrylated high-amylose maize
starches increases the proportion of IL-10-producing colonic
Foxp3+ Tregs in speciﬁc pathogen-free (SPF) mice to a greater
extent than diets containing propionylated and acetylated starches
[75]. In line with these results, Arpaia et al. showed that adminis-
tration of butyrate by diet or by enema leads to an increase in colo-
nic Foxp3+ Tregs in SPF mice [76]. This increase was dependent on
CNS1, an intronic enhancer required for the extrathymic conver-
sion of Tregs, demonstrating that butyrate speciﬁcally promotes
Treg development by the extrathymic induced pathway [76]. In
light of these ﬁndings, we are exploring the possibility that the
ability of a Clostridia-containing microbiota to protect against food
allergen sensitization is mediated, at least in part, through SCFA
activity. Of note, Clostridium species are major producers of SCFAs
[73] and GF mice colonized with a mixed population of Clostridia
have higher levels of cecal acetate and butyrate than GF controls
[75] (unpublished data).
SCFAs mediate their effects through two known mechanisms:
(1) direct inhibition of histone deacetylases to inﬂuence gene
expression and (2) signaling through the G-protein coupled recep-
tors (GPCR) GPR41, GPR43, and GPR109A [73]. To date, studies on
the mechanism by which SCFAs induce the differentiation of
Foxp3+ Tregs have focused on the former function, with both
Furusawa et al. and Arpaia et al. demonstrating that butyrate treat-
ment enhances the acetylation of histone H3 at the Foxp3 promoter
[75,76]. Whether or not GPCR signaling is also required is less clear.
Smith et al reported that GPR43 signaling is needed for propionate
induced expansion of Foxp3+ Tregs [74]. With regard to butyrate,
one study has implicated a role for signaling via GPR109A, as treat-
ment of WT but not Gpr109a/ CD11b+ macrophages and CD11c+
DCs with butyrate or niacin (another ligand of GPR109A) enhances
their ability to promote the differentiation of Tregs [77]. Notably,
the authors found that butyrate and niacin increased the expres-
sion of Aldh1a1 in cultured APCs in a GPR109A-dependent manner,
implying that butyrate signaling via GPR109A induces Treg differ-
entiation by promoting RA production from APCs [77]. However,
results from Arpaia et al disagree with the requirement for
GPR109A, as they demonstrate that pre-treatment of WT and
Gpr109a/ DCs with butyrate induces Tregs to a similar extent
[76]. How signaling via these three identiﬁed GPCRs cooperate to
mediate SCFA function in various contexts will need to be further
addressed.
An interesting question arising from these studies is whether
the colonic Foxp3+ Tregs induced by SCFAs are dietary antigen-spe-
ciﬁc and/or bacteria-speciﬁc, and how their expansion may inﬂu-
ence oral tolerance in the small intestine. It is important to
highlight that the studies above have focused on the expansion
of Foxp3+ Tregs speciﬁcally in the colon. Interestingly, Furusawa
et al. have demonstrated that a butyrate-containing diet promotes
the differentiation of colonic OVA-speciﬁc OT-II Foxp3+ T cells fol-
lowing the adoptive transfer of naïve OTII CD4+ T cells and oral
administration of OVA [75]. The same was shown by Singh et al
with niacin via GPR109A signaling, where administration of niacin
to antibiotic-treated WT mice led to a greater increase in the
percentage of OT-II Foxp3+ T cells in the colon than seen in antibi-otic-treated Gpr109a/ mice [77]. These results raise the possibil-
ity that SCFAs promote oral tolerance by facilitating the conversion
of dietary antigen-speciﬁc Foxp3+ Tregs. Indeed, the ﬁnding that
butyrate increases Aldh1a1 expression in gut APCs suggests that
this is the case, as RA is a known prerequisite for the differentiation
of dietary antigen-speciﬁc Foxp3+ Tregs. Whether or not a similar
expansion occurs in the small intestine, or how it is that these colo-
nic dietary antigen-speciﬁc Tregs inﬂuence immune responses to
antigen in the small intestine, warrants exploration and is further
discussed below. Additionally, it is likely that SCFAs also promote
the differentiation of bacteria-speciﬁc Foxp3+ Tregs. In support of
this, a butyrate-containing diet failed to increase colonic Treg fre-
quencies in GF mice [75], implying that Tregs may be induced by
SCFAs following the recognition of bacterial antigens.7. Connecting bacteria-derived signals in the colon to non-
responsiveness to dietary antigen in the small intestine
How signals derived from commensal bacteria in the colon
shape immune responses to dietary antigens in the small intestine
remains an open question (Fig. 2). The ability of commensal bacte-
ria to inﬂuence immune responses at sites far beyond the colon has
been demonstrated in several disease models including diabetes
[78], arthritis [79], experimental autoimmune encephalomyelitis
[80,81], and allergic airway inﬂammation [82]. One mechanism
by which commensal bacteria may exert far-reaching effects is
through lymphocyte migration. As mentioned earlier, it is accepted
that naïve CD4+ T cells, upon activation in the MLN and PP, are
imprinted with homing receptors that drive them towards the
small intestinal or colonic LP. While homing to the small intestine
depends on the cell surface molecules a4b7 and CCR9 [83], homing
to the colon relies on a4b7 and signaling via GPR15 [84]. These dis-
tinct homing requirements imply that immune responses are
highly compartmentalized within the GALT. However, this com-
partmentalization may not be completely rigid. Lymphocytes from
the colon could transiently migrate to the small intestine through
the connected network of lymphatics in the GALT [85] or through
the systemic circulation [86]. In support of the latter possibility,
Wu et al. found that a4b7+Th17 cells induced by segmented ﬁlamen-
tous bacteria in the small intestine were present in the spleens of
arthritic K/BxN mice and contributed to exacerbated arthritis [79].
How it is that effector T cells already imprinted to home to a spe-
ciﬁc location can then populate other sites of the body was not
addressed.
It is also possible that cytokines produced by bacteria-induced
lymphocyte populations circulate to other locations where they
may direct immune responses. We found that Clostridia promote
the production of IL-22 by CD4+ T cells and RORct+ ILCs in the colon
and regulate allergen uptake in the small intestine. Much lower
numbers of Clostridia colonize the ileum of both mice [41] and
humans [3], although in our hands, induction of IL-22 is undetect-
able in this site. It may be that IL-22 circulates through the blood-
stream or lymph to reach the small intestine, enriching the
concentration of this cytokine to strengthen the epithelial barrier
against allergen uptake. Colonic Foxp3+ Tregs may also exert their
effects in a similar fashion, releasing anti-inﬂammatory cytokines
that reach the small intestine to promote a tolerogenic environ-
ment (Fig. 2).
Another possibility is that bacteria-derived metabolites travel
outside the colon via the bloodstream and exert effects at distal
sites. Of note, SCFAs are known to circulate in the blood and have
been detected in the portal, hepatic and peripheral veins [87].
Recently, circulating SCFAs have been shown to protect against
allergic airway inﬂammation. Mice fed a high-ﬁber diet had
increased levels of SCFAs in both the cecum and the blood and
Fig. 2. How do immune responses to bacteria in the colon inﬂuence the induction of tolerance to dietary antigens absorbed in the small intestine? Immune cells, such as
Foxp3+ Tregs, induced by commensal Clostridia and/or their metabolites, may reach the small intestine by migrating via the connected network of lymphatics in the GALT or
through the systemic circulation. Cytokines produced by bacteria-induced immune cells in the colon could similarly circulate and reach the small intestine. Short chain fatty
acids (SCFAs) can enter the bloodstream and modulate immune responses at distal sites. Aside from the migration of cells and molecules, Clostridia present in the small
intestine itself may induce local immune responses that contribute to the maintenance of non-responsiveness to dietary antigen.
S. Cao et al. / FEBS Letters 588 (2014) 4258–4266 4263were protected against inﬂammation following intranasal admin-
istration of house dust mite extract [88]. Thus, to promote toler-
ance to dietary antigens, SCFAs produced by bacteria in the colon
could feedback through the bloodstream to induce Foxp3+ Treg dif-
ferentiation in the small intestine. Of note, Trompette et al. found
that SCFA-mediated protection against allergic airway inﬂamma-
tion was not due to Foxp3+ Tregs, as populations of Foxp3+ Tregs
did not expand in the lung draining lymph nodes [88]. Instead,
they propose that circulating SCFAs inﬂuence DC hematopoiesis,
populating the lungs with DCs that have an altered activation state
and an impaired ability to promote Th2 cells. While the effects of
SCFAs on hematopoiesis may also inﬂuence non-responsiveness
to dietary antigen, it is likely that circulating SCFAs shape immune
responses in the lung and gut environments via different
mechanisms.
Beyond the movement of cells, cytokines, and metabolites from
the colon, it is important not to overlook the immunoregulatory
potential of commensal bacteria in the small intestine itself.
Though present at much lower microbial densities, bacteria in
the small intestine may regulate tolerogenic immune responses
that inﬂuence oral tolerance.
8. Implications for the development of novel
immunotherapeutics to prevent or treat food allergy
The rising prevalence of food allergies in Western nations has
become a public health crisis that requires immediate attention.
The urgency of the problem is exacerbated by the fact that noeffective treatment for food allergies is currently available. 90% of
food allergies are attributable to only eight major types of food:
milk, eggs, shellﬁsh (particularly crustaceans), ﬁsh, peanuts, soy-
beans, tree nuts and wheat [44]. Clinically, allergic disease follows
a characteristic natural history, often referred to as the ‘‘allergic
march’’, which appears ﬁrst as atopic dermatitis in infancy and is
then followed by food allergy, allergic rhinitis and asthma in later
years [89]. Atopic children typically exhibit transient allergic
responses to milk, soybeans, eggs and wheat. Allergic responses
to peanuts, tree nuts and shellﬁsh, however, are likely to result
in life-long anaphylactic hypersensitivity. Most of the immuno-
dominant allergens in each of these foods have been characterized
but their biochemistry has not yet yielded clues that explain their
potent allergenicity [44].
Our rapidly growing understanding of the role of our gut micro-
biota in allergic disease opens up an exciting avenue of research
into therapeutic interventions that can harness the immunoregula-
tory potential of host-commensal interactions. There is already an
extensive literature documenting the efﬁcacy of live, health pro-
moting microorganisms (probiotics) as a treatment for allergic dis-
ease [90]. Much of this work has focused on readily culturable
Lactobacillus and Biﬁdobacterium species that predominate in the
infant gut [91]. Treatment seems to be most efﬁcacious when
administered to pregnant mothers both pre- and post-natally dur-
ing their children’s infancy [92–98]. Indeed, infancy marks a period
of rapid development for the gut microbiota, when its composition
is inherently unstable and likely to be receptive to therapeutic
manipulation [99].
4264 S. Cao et al. / FEBS Letters 588 (2014) 4258–4266Lactobacillus rhamnosus GG (LGG) is among the probiotic formu-
lations most often associated with clinical efﬁcacy [94,95,98]. Berni
Canani et al. have recently demonstrated that dietary management
with an extensively hydrolyzed casein formula (EHCF) containing
LGG results in a higher rate of tolerance acquisition in infants with
cow’s milk allergy (CMA) than treatment with EHCF alone or with
other non-milk based formulas [100]. We hypothesized that this
effect is attributable, in part, to an inﬂuence of this dietary inter-
vention on the composition of the gut microbiota and collaborated
with this group to test this hypothesis [101]. We found that, before
treatment, the gut microbiota of allergic infants exhibits an accel-
erated ecological succession to a community structure more typi-
cal of adults. When we examined the inﬂuence of LGG treatment
on the composition of the gut microbiota we found that it does
not result in an increased abundance of lactobacilli detectable in
the feces of the treated infants. Instead, treatment with EHCF plus
LGG, but not a rice protein hydrolyzed formula (RHF), is associated
with changes in microbial community structure that include the
expansion of butyrate-producing Clostridia. CMA infants treated
with EHCF plus LGG, but not RHF, had signiﬁcantly higher levels
of butyrate detectable in their feces and an accelerated acquisition
of tolerance to cow’s milk [101].
These ﬁndings are particularly relevant in light of the recent
advances in our understanding, discussed above, of how speciﬁc
bacterial species and their metabolites inﬂuence food allergen sen-
sitization. The discovery that butyrate-producing Clostridia
become more prevalent in this cohort of treated infants corrobo-
rates the ﬁndings in our mouse model that a Clostridia-containing
microbiota confers protection against food allergen sensitization.
Oral desensitization protocols are already showing some efﬁcacy
for the treatment of food allergy in clinical trials [102]. Our data
suggest that strategies that pair Clostridia enrichment of the gut
microbiota with these tolerance-inducing protocols may potenti-
ate antigen-speciﬁc tolerance to prevent or treat food allergy.
In this regard, our mouse model provides a valuable pre-clinical
foundation for elucidating more effective strategies to restore or
enhance the immunoregulatory capacity of commensal bacteria.
For instance, further research into how Clostridia initiate protec-
tive immune responses, be it through metabolites such as SCFAs
or through direct signaling to receptors on host cells, will acceler-
ate the development of novel forms of probiotic intervention. The
relevance of SCFAs in intestinal health may inform strategies to
modulate ﬁber intake as a means of promoting tolerance to dietary
antigens. Indeed, butyrate-producing Clostridia species are known
to be particularly sensitive to dietary manipulation, increasing in
abundance with increased ﬁber intake [103]. In addition, the devel-
opment of agonists that mimic Clostridia’s interaction with its host
could help to maintain immunoregulatory signals when the com-
position of the microbiota is disturbed. Overall, a deeper under-
standing of the role of the gut microbiota in regulating responses
to food holds much promise for new immunotherapeutics that
can combat the precipitous rise in the prevalence of food allergies.
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